Internal link ProQR Announces Second Quarter 2025 Operating and Financial Results août 07, 2025 at 11:00 AM UTC
Internal link ProQR Announces Upcoming Presentation at RNA Editing Summit juillet 28, 2025 at 12:00 PM UTC
Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP juin 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences mai 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth avril 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results mars 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Added to NASDAQ Biotechnology Index décembre 24, 2018 at 12:00 PM UTC
Internal link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 décembre 18, 2018 at 03:27 PM UTC
Internal link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 décembre 17, 2018 at 04:52 PM UTC
Internal link ProQR Announces Strategic Changes to the Management Team and Key New Hires décembre 13, 2018 at 12:00 PM UTC
Internal link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 décembre 10, 2018 at 12:00 PM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients décembre 04, 2018 at 12:00 PM UTC
Internal link ProQR to Present at the Evercore ISI HealthConX Conference novembre 20, 2018 at 12:00 PM UTC
Internal link ProQR Announces Financial Results for the Third Quarter of 2018 novembre 07, 2018 at 12:00 PM UTC
Internal link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference octobre 31, 2018 at 11:00 AM UTC
Internal link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals octobre 30, 2018 at 10:15 PM UTC
Internal link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals octobre 29, 2018 at 11:33 AM UTC
Internal link ProQR to Present at the Chardan Genetic Medicines Conference octobre 02, 2018 at 11:00 AM UTC
Internal link ProQR Announces Presentations at the OTS Annual Meeting septembre 24, 2018 at 11:00 AM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares septembre 11, 2018 at 08:01 PM UTC
Internal link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares septembre 07, 2018 at 08:21 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares septembre 05, 2018 at 08:01 PM UTC